Hypereosinophilic SyndromeEOSINOPHILIMNCT02581514
Eosinophilia Diagnosis
A study testing Scheduled exams and diagnosis in people with Hypereosinophilic Syndrome, run by University Hospital, Limoges at 1 site in France.
Trial summary
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine. Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypereosinophilic Syndrome
- What is being tested?
- Scheduled exams and diagnosis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 53 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2015to 3 May 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient having one of the three following criteria:
- hypereosinophilia> 1500 / mm3, checked on at least two samples (interval between 2 samples at the discretion of the clinician)
- or hypereosinophilia> 500 cells / mm3 and organ damage with infiltration NCB proven by pathological examination,
- or hypereosinophilia> 500 cells / mm3 and found consistently for at least six months (present on all controls carried out before inclusion).
- Patient affiliated or beneficiary of a social security system
- Patient who signed the informed consent
Who cannot join
- Patient with solid tumors known (under chemotherapy or planned)
- Patient unable to understand or to adhere to the Protocol
- Patient unable to give consent
- Pregnant or breastfeeding women
- Patient already participating in an interventional trial
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
Read more
The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia.
We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.
Read the detailed description
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening
Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia.
The contribution to the diagnosis of a hierarchical strategy for prescribing additional tests , based on clinical examination as well as some simple diagnostic tests, has never been evaluated
We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.
All types of patients are tacked into account: those coming from the university hospital, referred by general practitioners or by other hospitals.
In addition we address the internal medicine patients ,but also those of Hematology and Infectious Diseases. A comparison of these various groups would be relevant, since disorders that may be different.
Once enrolled, the patient is drived by the investigator through the various steps and exams imposed by the algorithm.
Indeed, during 5 months (Day1 5, 43, 71 , 85 , 99 ,113 and month 5), patient is asked to comply to the various exams and assessment imposed by the algorithm and that should lead to a diagnosis
- Conditions
- Hypereosinophilic Syndrome
- Being tested
- Scheduled exams and diagnosis
- Keywords
- decision algorithm
- Medical subject headings
- Hypereosinophilic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Scheduled exams and diagnosisOther
Scheduled exams and diagnosis circuit as imposed by the algorithm
| Study group | Role | What they receive |
|---|---|---|
| Algorithm | Experimental | Eosinophilia is assessed following the diagnosis algorithm Receives: Other: Scheduled exams and diagnosis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients having correctly follow the diagnosis algorithm
This outcome measure how many patients have correctly followed the diagnosis algorithm
Measured: 5 months
Secondary outcomes (3)
Rate of diagnosis
Evaluate the rate of diagnosis using our diagnosis algorithm
Measured: 5 months
Assess the time to diagnosis
Assess the time to diagnosis
Measured: 5 months
Description of diagnosis
To compare the diagnosis found in our study to the published cohort.
Measured: 5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2015 (estimated)
- Study startOct 2015
- Primary completionSep 2019
- Study completion3 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypereosinophilic SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 53 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Limoges
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Holy BEZANAHARY, Principal investigator, University Hospital, Limoges
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02581514
- Sponsor's protocol ID
- I14028/EOSINOPHILIM
- Acronym
- EOSINOPHILIM
- Status last verified
- Jun 2019
- First submitted
- 19 Oct 2015
- Last updated
- 24 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia
- ClinicalTrials.gov ID
- NCT02581514
- Acronym / sponsor ID
- EOSINOPHILIM / I14028/EOSINOPHILIM
- Conditions
- Hypereosinophilic Syndrome
- Keywords
- decision algorithm
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 53 participants (estimated)
- Lead sponsor
- University Hospital, LimogesUniversity, hospital or other
- Study start
- Oct 2015 (actual)
- Primary completion
- Sep 2019 (actual)
- Study completion
- 3 May 2021 (actual)
- First posted
- 21 Oct 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia.
We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.
Detailed description
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening
Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied.
The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia.
The contribution to the diagnosis of a hierarchical strategy for prescribing additional tests , based on clinical examination as well as some simple diagnostic tests, has never been evaluated
We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis.
This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.
All types of patients are tacked into account: those coming from the university hospital, referred by general practitioners or by other hospitals.
In addition we address the internal medicine patients ,but also those of Hematology and Infectious Diseases. A comparison of these various groups would be relevant, since disorders that may be different.
Once enrolled, the patient is drived by the investigator through the various steps and exams imposed by the algorithm.
Indeed, during 5 months (Day1 5, 43, 71 , 85 , 99 ,113 and month 5), patient is asked to comply to the various exams and assessment imposed by the algorithm and that should lead to a diagnosis
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Algorithm | Experimental | Other: Scheduled exams and diagnosisEosinophilia is assessed following the diagnosis algorithm |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patient having one of the three following criteria:
- Patient affiliated or beneficiary of a social security system
- Patient who signed the informed consent
Key exclusion criteria (5 listed)
- Patient with solid tumors known (under chemotherapy or planned)
- Patient unable to understand or to adhere to the Protocol
- Patient unable to give consent
- Pregnant or breastfeeding women
- Patient already participating in an interventional trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Scheduled exams and diagnosisScheduled exams and diagnosis circuit as imposed by the algorithm | Other | Algorithm |
Primary outcome
Number of patients having correctly follow the diagnosis algorithm
Time frame: 5 months
This outcome measure how many patients have correctly followed the diagnosis algorithm
3 secondary outcomes
Rate of diagnosis
Time frame: 5 months
Assess the time to diagnosis
Time frame: 5 months
Description of diagnosis
Time frame: 5 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
Related trials for Hypereosinophilic Syndrome
RecruitingObservational study
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Eosinophilia, Hypereosinophilic Syndrome
RecruitingPhase 3
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Active, not recruitingPhase 3
SIM0718 Treatment of Asthma Clinical Study
Asthma; Eosinophilic
Active, not recruitingPhase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Hypereosinophilic Syndrome
RecruitingPhase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Eosinophilic Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Holy BEZANAHARY principal investigator
University Hospital, Limoges
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Scheduled exams and diagnosis in people with Hypereosinophilic Syndrome, run by University Hospital, Limoges at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients having correctly follow the diagnosis algorithm (time frame: 5 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.